Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 20,129 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 20,129 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the sale, the director directly owned 12,546 shares in the company, valued at $520,784.46. This trade represents a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kiniksa Pharmaceuticals International Trading Up 0.2%

Shares of Kiniksa Pharmaceuticals International stock traded up $0.10 during midday trading on Wednesday, reaching $41.47. The company had a trading volume of 389,886 shares, compared to its average volume of 600,411. The stock has a fifty day simple moving average of $39.97 and a 200 day simple moving average of $34.74. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 92.16 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm’s quarterly revenue was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.18) earnings per share. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently modified their holdings of KNSA. Danske Bank A S bought a new position in Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $1,180,000. Castleark Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $6,160,000. PharVision Advisers LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $261,000. Voleon Capital Management LP acquired a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter worth $3,462,000. Finally, Prosperity Wealth Management Inc. bought a new position in Kiniksa Pharmaceuticals International during the third quarter worth about $540,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KNSA. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Wedbush reissued an “outperform” rating and set a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, December 2nd. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.